Health state utilities for non small cell lung cancer

<p>Abstract</p> <p>Background</p> <p>Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values fo...

Full description

Bibliographic Details
Main Authors: Bhalla Shkun, Gavriel Sonia, Stafford Megan, Nafees Beenish, Watkins Jessamy
Format: Article
Language:English
Published: BMC 2008-10-01
Series:Health and Quality of Life Outcomes
Online Access:http://www.hqlo.com/content/6/1/84
id doaj-537667a3a9fa46cea02f54f92cc6f34a
record_format Article
spelling doaj-537667a3a9fa46cea02f54f92cc6f34a2020-11-24T21:34:58ZengBMCHealth and Quality of Life Outcomes1477-75252008-10-01618410.1186/1477-7525-6-84Health state utilities for non small cell lung cancerBhalla ShkunGavriel SoniaStafford MeganNafees BeenishWatkins Jessamy<p>Abstract</p> <p>Background</p> <p>Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash and hair loss.</p> <p>Methods</p> <p>Existing health state descriptions of metastatic breast cancer were revised to make them suitable as descriptions of metastatic NSCLC patients on second-line treatment. The existing health states were used in cognitive debrief interviews with oncologists (n = 5) and oncology specialist nurses (n = 5). Changes were made as suggested by the clinical experts. The resulting health states (n = 17) were piloted and used in a societal based valuation study (n = 100). Participants rated half of the total health states in a standard gamble interview to derive health state utility scores. Data were analysed using a mixed model analysis.</p> <p>Results</p> <p>Each health state described the symptom burden of disease and impact on different levels of functioning (physical, emotional, sexual, and social). The disutility related to each disease state and toxicity was estimated and were combined to give health state values. All disease states and toxicities were independent significant predictors of utility (p < 0.001). Stable disease with no toxicity (our base state) had a utility value of 0.653. Utility scores ranged from 0.673 (responding disease with no toxicity) to 0.473 for progressive disease.</p> <p>Conclusion</p> <p>This study reflects the value that society place on the avoidance of disease progression and severe toxicities in NSCLC.</p> http://www.hqlo.com/content/6/1/84
collection DOAJ
language English
format Article
sources DOAJ
author Bhalla Shkun
Gavriel Sonia
Stafford Megan
Nafees Beenish
Watkins Jessamy
spellingShingle Bhalla Shkun
Gavriel Sonia
Stafford Megan
Nafees Beenish
Watkins Jessamy
Health state utilities for non small cell lung cancer
Health and Quality of Life Outcomes
author_facet Bhalla Shkun
Gavriel Sonia
Stafford Megan
Nafees Beenish
Watkins Jessamy
author_sort Bhalla Shkun
title Health state utilities for non small cell lung cancer
title_short Health state utilities for non small cell lung cancer
title_full Health state utilities for non small cell lung cancer
title_fullStr Health state utilities for non small cell lung cancer
title_full_unstemmed Health state utilities for non small cell lung cancer
title_sort health state utilities for non small cell lung cancer
publisher BMC
series Health and Quality of Life Outcomes
issn 1477-7525
publishDate 2008-10-01
description <p>Abstract</p> <p>Background</p> <p>Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash and hair loss.</p> <p>Methods</p> <p>Existing health state descriptions of metastatic breast cancer were revised to make them suitable as descriptions of metastatic NSCLC patients on second-line treatment. The existing health states were used in cognitive debrief interviews with oncologists (n = 5) and oncology specialist nurses (n = 5). Changes were made as suggested by the clinical experts. The resulting health states (n = 17) were piloted and used in a societal based valuation study (n = 100). Participants rated half of the total health states in a standard gamble interview to derive health state utility scores. Data were analysed using a mixed model analysis.</p> <p>Results</p> <p>Each health state described the symptom burden of disease and impact on different levels of functioning (physical, emotional, sexual, and social). The disutility related to each disease state and toxicity was estimated and were combined to give health state values. All disease states and toxicities were independent significant predictors of utility (p < 0.001). Stable disease with no toxicity (our base state) had a utility value of 0.653. Utility scores ranged from 0.673 (responding disease with no toxicity) to 0.473 for progressive disease.</p> <p>Conclusion</p> <p>This study reflects the value that society place on the avoidance of disease progression and severe toxicities in NSCLC.</p>
url http://www.hqlo.com/content/6/1/84
work_keys_str_mv AT bhallashkun healthstateutilitiesfornonsmallcelllungcancer
AT gavrielsonia healthstateutilitiesfornonsmallcelllungcancer
AT staffordmegan healthstateutilitiesfornonsmallcelllungcancer
AT nafeesbeenish healthstateutilitiesfornonsmallcelllungcancer
AT watkinsjessamy healthstateutilitiesfornonsmallcelllungcancer
_version_ 1725947160461049856